ARCHIVES

FDA Approves Erbitux for Head & Neck Cancer.

This article is from The Cancer Letter archive.

Vol. 32 No. 08 | March 3, 2006

Download PDF Visit The Full Archive

Related Articles

In Brief: Gene Therapy Pioneer Michael Blaese To Leave NIH For Biotechnology Firm

January 16, 1998

Local Labs Not As Accurate As Central Testing For HER2

August 30, 2002

The 99th turned Out Well For Cancer Program, But Several Important Issues Await 100th Congress

October 31, 1986

MD Anderson’s Balance Sheet is Issue No. 1 For DePinho’s “Moon Shots Program”

October 12, 2012

NCI Largely Unaffected By NIH Translational Research Center

February 11, 2011

DCPC Board Approves Concepts Of Six New RFAs Totaling $9.3 Million A Year

May 11, 1984